文献速递疼痛医学区域麻醉与超声

关节内皮质类固醇与富血小板血浆治疗颈椎小关节源性疼痛的随机临床试验

Intra-articular corticosteroid injections versus platelet-rich plasma as a treatment for cervical facetogenic pain: a randomized clinical trial.
PubMed 文献 · Reg Anesth Pain Med · 2026-01-05

单中心随机双盲对照试验纳入40例颈椎小关节源性疼痛患者,比较关节内注射贫白细胞低浓度富血小板血浆与不含局麻药的皮质类固醇的效果。两组在6个月内疼痛强度变化无显著组间差异,但均在1个月时疼痛显著下降;富血小板血浆组1个月时疼痛自我效能改善更明显且操作疼痛更轻,不良事件无显著差异。

要点

  • 低浓度富血小板血浆与皮质类固醇注射对颈椎小关节源性疼痛6个月内的疼痛强度改善相似。
  • 两组1个月时疼痛均较基线显著下降,富血小板血浆组达临床显著改善。
  • 富血小板血浆组1个月时疼痛自我效能提升更大,且操作疼痛更轻。

核心结论

  • 富血小板血浆与皮质类固醇注射对颈椎小关节源性疼痛强度(1个月时)和自评残疾(3及6个月时)的改善相似。
  • 疼痛自我效能存在显著交互作用,富血小板血浆组1个月时改善更大。
  • 两组不良事件发生率均低且相似,但富血小板血浆组操作疼痛更轻。

研究设计与样本

  • 单中心随机双盲对照试验,共40名参与者。
  • 参与者随机接受贫白细胞低浓度富血小板血浆注射或不含局麻药的皮质类固醇注射,均在透视下注入颈椎小关节。
  • 通过电话在1、3和6个月收集结局以评估治疗效果。

主要发现

  • 数字评定量表评分的组别与时间交互作用不显著(p>0.05),表明6个月内两组疼痛强度效果相似。
  • 两组治疗后1个月疼痛强度较基线均显著下降(p=0.02),富血小板血浆组同时达临床显著下降。
  • 疼痛自我效能在干预后1个月存在显著交互作用(p=0.04),富血小板血浆组增加更大。
  • 自评残疾无显著交互作用,但两组在治疗后3和6个月较基线均显著降低(p<0.01)。
  • 不良事件组间无显著差异,但富血小板血浆组报告的操作疼痛显著更少(p=0.02)。

临床怎么用

  • 对于颈椎小关节源性疼痛,富血小板血浆与皮质类固醇注射均可考虑用于短期疼痛和残疾改善。
  • 若关注操作疼痛或疼痛自我效能,富血小板血浆可能更有优势。

局限性

  • 单中心设计可能限制结果外推性。
  • 样本量较小(40例),可能影响统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The study's primary objective was to compare the effectiveness of intra-articular platelet-rich plasma injections versus corticosteroid injections for the treatment of cervical facetogenic pain. Secondary aims were to compare self-rated disability, pain self-efficacy, and the safety of the procedure between groups. METHODS: A single-site randomized double-blind controlled trial with 40 participants assigned to receive either leucocyte-poor, low-concentrate platelet-rich plasma injections or corticosteroid injection without local anesthetic into the cervical facet joint under fluoroscopy. Outcomes were collected via telephone at 1, 3, and 6 months to determine treatment effectiveness. RESULTS: Low-concentrate platelet-rich plasma and corticosteroid injections had similar effects on cervical facetogenic pain intensity over a 6-month period post injection as demonstrated by a non-significant group-by-time interaction for Numeric Rating Scale scores (p>0.05). However, both groups showed a statistically significant decrease in cervical facetogenic pain intensity 1 month post treatment compared with baseline (p=0.02), while the platelet-rich plasma group also demonstrated a clinically significant decrease in pain intensity at the same time point. There was a significant interaction at 1 month post intervention for pain self-efficacy (p=0.04), with the platelet-rich plasma injection group showing a larger increase in pain self-efficacy compared with the corticosteroid injection group. No significant interaction was observed for self-rated disability; however, significant reductions were shown at 3 and 6 months post treatment compared with baseline in both groups (p<0.01). No significant differences between groups were reported for adverse events; however, those receiving platelet-rich plasma injection reported significantly less procedural pain (p=0.02). CONCLUSION: Both platelet-rich plasma and corticosteroid injections induced similar improvements in cervical facetogenic pain intensity (1 month post) and self-rated disability (3 and 6 months post). Pain self-efficacy demonstrated a significant interaction with platelet-rich plasma injection showing greater improvement 1 month post. Additionally, both treatments exhibited a similar low prevalence of adverse events; however, those receiving platelet-rich plasma injection reported less procedural pain.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Allison DJ, Ebrahimzadeh S, Muise S, et al. Intra-articular corticosteroid injections versus platelet-rich plasma as a treatment for cervical facetogenic pain: a randomized clinical trial. Reg Anesth Pain Med. 2026. PMID: 39542641. doi:10.1136/rapm-2024-105889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。